Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

2seventy bio

- PMLiVE

UK scientists reveal promising new treatment strategy for acute myeloid leukaemia

The aggressive form of blood cancer is responsible for more than 3,000 new cases in the UK every year

- PMLiVE

Bristol Myers Squibb to acquire Orum’s experimental blood cancer therapy for up to $180m

ORM-6151 has been cleared for early-stage testing in AML or myelodysplastic syndromes

- PMLiVE

2Seventy bio’s partner pauses phase 1 leukaemia study following patient death

The death occurred in the first patient treated with the CAR-T cell therapy at the second dosing level

- PMLiVE

BMS and 2seventy bio report positive phase 3 results for multiple myeloma treatment

An estimated 35,000 new cases of multiple myeloma will be diagnosed in the US this year

- PMLiVE

FDA approves Rigel’s Rezlidhia for acute myeloid leukaemia

Phase 2 data showed a complete remission rate of 35% and median duration of 25.9 months

- PMLiVE

Bristol Myers Squibb’s acute myeloid leukaemia oral maintenance therapy recommended by NICE

Phase 3 trial results show Onureg offers significantly longer overall and relapse-free survival

- PMLiVE

EMA accepts Otsuka and Astex’s marketing authorisation application for acute myeloid leukaemia treatment 

The application is supported by results from a phase 3 trial demonstrating an exposure equivalence to the current standard of care for AML

- PMLiVE

BMS and 2seventy bio announce positive results for multiple myeloma treatment

The results show that Abecma ‘significantly improves’ progression-free survival in relapsed and refractory multiple myeloma

- PMLiVE

FDA lifts hold on Gilead’s clinical trials for leukaemia

Following a review of the safety data, enrolment can be resumed for the MDS and AML clinical trials

- PMLiVE

BMS and 2seventy bio move away from CAR-T programme

The two companies will focus their efforts on furthering the growing success of BMS’ therapy Abecma

- PMLiVE

bluebird bio splits to create new oncology firm 2seventy bio

2seventy bio gets the company’s immune-oncology cell therapies products, while bluebird bio will continue its work on severe genetic diseases

- PMLiVE

bluebird bio provides update on 2seventy bio spin-off

The company has also announced the appointment of two new board members, Najoh Tita-Reid and Sarah Glickman

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links